Scientific aspects of supplying blood to distant military theaters

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 694-699

  Johnson, Viviana V ^a   Swiatkowski, Sean A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Blood substitutes; Blood transport; Frozen blood; Military; Walking blood bank

Indexed keywords

HEMOGLOBIN; OXYGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

APHERESIS; ARMY; BLEEDING; BLOOD; BLOOD BANK; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTAINER; ERYTHROCYTE; FREEZE DRYING; HEALTH SERVICE; HEMOPHILIA; HUMAN; PLASMA; PLASMA FACTOR; PRIORITY JOURNAL; RESUSCITATION; REVIEW; TECHNOLOGY; THROMBOCYTE;

BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; HUMANS; MILITARY MEDICINE; WAR;

EID: 34848842502     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282ef477f     Document Type: Review

References (52)

1. Hoyt DB, Coimbra R, Potenza B. Management of acute trauma. In: Townsend CM, Beauchamp DR, Evers BM, Mattox KL, editors. Sabiston textbook of surgery, 17th ed. Philadelphia, Pennsylvania: Saunders; 2004. pp. 483-529.
2. Gofrit ON, Leibovici D, Shapira SC. The Trimodal death distribution of trauma victims: military experience from the Lebanon War. Mil Med 1997; 162:24-26.
3. MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39-44.
4. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary Task Force. J Thromb Haemost 2005; 3:640-648.
5. Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006; 46:685-686. This article describes the importance of recognizing and treating existing coagulopathy early in patients who have suffered significant trauma.
6. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate and platelet transfusion in trauma. J Trauma 2006; 60:S51-S58. The authors of this article review published data of large consecutive patient series. They conclude that early use of plasma in massive transfusion in a ratio of 2:3 or 1:1 with units of red blood cells and use of platelets as soon as after seven to eight units of red blood cells reduces the incidence of coagulopathy in massively transfused individuals.
7. Beekley AC, Starnes BW, Sebesta JA. Lessons learned from modern military surgery. Surg Clin North Am 2007; 87:157-184. This article describes new improvements that impact combat casualty care using data collected during current operations and focuses on lessons learned.
8. Beekley AC. United States military surgical response to modern large-scale conflicts: the ongoing evolution of a trauma system. Surg Clin North Am 2006; 86:689-709.
9. Bolan CD, Webster NR. Anesthesia and perioperative care of the combat casualty. In: Zajtchuk R, editor. Military transfusion practice textbook of military medicine. Washington, District of Columbia: Department of the Army, Borden Institute; 1995. pp. 341-373.
10. Stinger H, Rush R. The army forward surgical team: update and lessons learned, 1997-2004. Mil Med 2006; 171:269-272. The article describes the concept of forward surgical teams, explains the benefits of surgical care very near to combat sites, and recommends that forward surgical teams have access to several blood products and factors, not just red blood cells.
11. American Association of Blood Banks. Standards for blood banks and transfusion services, Bethesda, MD: American Association of Blood Banks, 2005.
12. US Government Printing Office. CFR21. Part 640.4 (h). Code of federal regulations. Washington, District of Columbia: US Government Printing Office; 2005.
13. Hess JR, Rugg N, Gormas JK, et al. RBC storage for 11 weeks. Transfusion 2001; 41:1586-1590.
14. Gambro BCT, Inc. 7-Day platelets and the PASSPORT study. Questions and answers. Lakewood, Colorado: Gambro BCT, Inc.; 2006.
15. Dumont LJ, AuBuchon JP, Whitely P, Herschel LH, et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002; 42:847-854.
16. Neel S. The military blood program. In: Medical support of the US army in Vietnam 1965-1970. Washington, District of Columbia: Department of the Army; 1991. pp. 114-126.
17. Rentas FJ, Macdonald VW, Houchens DM, et al. New insulation technology provides next-generation containers for 'iceless' and lightweight transport of RBCs at 1 to 10°C in extreme temperatures for over 78 h. Transfusion 2004; 44:210-216.
18. Sebesta J. Special lessons learned from Iraq. Surg Clin North Am 2006; 86:711-726. This article describes massive transfusion protocols in combat support hospitals, which include rFVIIa, activation of the walking blood bank, and use of fresh whole blood. The article describes the use of rFVIIa in combat support hospitals as playing a role in decreasing blood losses and reducing requirements.
19. Spinella PC, Grathwohl K, Holcomb J, et al. Risks associated with fresh warm whole blood compared to PRBC transfusions during combat. 165-S. Crit Care Med 2005; 33:A44.
20. Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole blood transfusion: a controversial military practice. J Trauma 2006; 61:181-184. The authors review all blood products administered to US military casualties in Operation Iraqi Freedom between March and December 2003, and evaluate the safety, efficacy, and logistics of fresh whole blood. The article illustrates how, in certain military situations, whole blood is safe and beneficial.
21. Repine TB, Perkins JG, Kauvar DS, Blackborne L. The use of fresh whole blood in massive transfusion. J Trauma 2006; 60:S59-S69. This article describes distinct advantages of fresh warm whole blood over component therapy observed by military physicians during the massive transfusion of acidotic, hypothermic, and coagulopathic trauma patients. The article illustrates the critical life-saving role of blood in a massive transfusion protocol used at the 31st Combat Support Hospital stationed in Baghdad in 2004-2005.
22. Hrezo RJ, Clark J. The walking blood bank: an alternative blood supply in military mass casualties. Disaster Manag Response 2003; 1:19-22.
23. Malsby R III, Frizzi J, Ray P, Raff J. Walking donor transfusion in a far forward environment. South Med J 2005; 98:809-810.
24. Department of Defense Health Affairs. Policy on the use of non-US Food and Drug Administration licensed blood products [memorandum]. Washington, District of Columbia: Department of Defense Health Affairs; 2001.
25. Lelkens CM, Koning JG, de Kort B, Floot IG, et al. Experiences with frozen blood products in the Netherlands military. Transfus Apher Sci 2006; 34:289-298. This article describes methods and logistics to maintain a frozen blood inventory used for military missions to reduce frequent shipments required by a liquid inventory.
26. Moss GS, Valeri CR, Brodine CE. Clinical experience with the use of frozen blood in combat casualties. N Engl J Med 1968; 278:747-752.
27. Hess JR. Red cell freezing and its impact on the supply chain. Transfus Med 2004; 14:1-8.
28. Valeri CR, Pivacek LE, Gray AD, et al. The safety and therapeutic effectiveness of human red cells stored at -80 degrees C for as long as 21 years. Transfusion 1989; 29:429-437.
29. Valeri CR. The in vitro quality of red blood cells frozen with 40 percentage (wt/vol) glycerol at -80 degrees C for 14 years, deglycerolized with the Haemonetics ACP 215, and stored at 4 degrees C in additive solution-1 or additive solution-3 for up to 3 weeks. Transfusion 2004; 44:990-995.
30. Daly PA, Schiffer CA, Aisner J, Wiernik PH. Successful transfusion of platelets cryopreserved for more than 3 years. Blood 1979; 54:1023-1027.
31. Valeri CR. Freezing human platelets with 6 percentage dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at -80 degrees C without postthaw processing. Transfusion 2005; 45:1890-1898.
32. American Association of Blood Banks, America's Blood Centers, and the American Red Cross. Circular of information for the use of human blood and blood components. 2002. http://www.fda.gov/cber/gdlns/crclr.pdf [Accessed 9 July 2007].
33. O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-h whole blood storage on plasma clotting factors. Transfusion 1999; 39:488-491.
34. Winslow RM. Red cell substitutes. Semin Hematol 2007; 44:51-59. This article illustrates the development of hemoglobin-based oxygen carrier technology by subdividing products into four generations, corresponding to major improvements. The article illustrates that vasoactivity of haemoglobin-based oxygen carriers is not only due to nitric oxide binding but is also caused by other mechanisms, including the binding of oxygen itself.
35. Winslow RM. Blood substitutes: basic principles and practical aspects. In: Hillyer CD, editor. Blood banking and transfusion medicine. Basic principles & practice. St Louis, Missouri: Churchill Livingstone; 2007.
36. Tsai AG, Cabrales P, Manjula BN, et al. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 2006; 108:3603. This article illustrates that vasoconstriction due to cell-free hemoglobin oxygen carriers is not solely related to nitric oxide scavenging, but factors such as molecular dimension, retention time, and gas-carrying properties may be responsible for regulating vascular tone and perfusion.
37. Ness PM, Cushing MD. Oxygen therapeutics. Pursuit of an alternative to the donor red blood cell. Arch Pathol Lab Med 2007; 131:734-741. This article describes the status of current and completed clinical trials involving hemoglobin-based oxygen carriers.
38. Jahr JS, Stewart LM, Mackenzie C, Bourke D, et al. Pivotal study: safety of polymerized bovine hemoglobin (HBOC-201, Hemopure) as compared to RBC in patients undergoing orthopedic surgery [abstract]. Anesthesiology 2002; 96:A243.
39. Moore EE, Johnson JL, Cheng AM, et al. Insights from studies of blood substitutes in trauma. Shock 2005; 24:197-205.
40. Napolitano L. Cumulative risks of early blood transfusion in trauma. J Trauma 2006; 60:S26-S34. This article describes current understanding of potential mechanisms mediating transfusion-associated adverse effects in trauma patients.
41. Dornan RK. Freeze-dried blood: a modern military miracle. Mil Med 1990; 155:512-513.
42. Kheirolomoom A, Satpathy GR, Torok Z, et al. Phospholipid vesicles increase the survival of freeze-dried human red blood cells. Cryobiology 2005; 51:290-305.
43. Blajchman MA. Novel platelet products, substitutes and alternatives. Transfus Clin Biol 2001; 8:267-271.
44. Fischer TH, Bode AP, Parker BR, et al. Primary and secondary hemostatic functionalities of rehydrated, lyophilized platelets. Transfusion 2006; 46:1943-1950. The results of in-vitro and in-vivo studies described in this article suggest that rehydrated, lyophilized platelets may stop bleeding by forming primary hemostatic plugs and providing a localized source for secondary hemostasis, but they do not build up occlusive pathologic clots.
45. 111In-oxinelabelled autologous fresh and lyophilized reconstituted platelets. Vox Sang 2005; 88:122-129.
46. Fischer TH, Merricks EP, Bode AP, et al. Thrombus formation with rehydrated, lyophilized platelets. Hematology 2002; 7:359-369.
47. Johansson PI, Eriksen K, Alsbjorn B. Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleeding secondary to major wound excision: a report of four cases. J Trauma 2006; 61:1016-1018.
48. Rizoli SB, Nascimento B Jr, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006; 61:1419-1425.
49. Weiskopf RB. Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang 2007; 92:281-288.
50. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care 2006; 10:R120.
51. Perkins JG, Schreiber MA, Wade CE, Holcomb JB. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007; 62:1095-1101. This article illustrates how administration of rFVIIa decreases the need for packed red blood cells in trauma patients who require massive transfusions.
52. Novo Nordisk A/S. Important drug warning. Letter from Novo Nordisk Inc. to healthcare professionals. Bagsvaerd, Denmark: Novo Nordisk A/S; 2005.